AURX.US Nuo Therapeutics Inc
- Market cap
- USD 52.8M
- P/E
- -
- P/B
- 41.78x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AURX.US undervalued?
Graham numberThe Graham number of Nuo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nuo Therapeutics Inc fundamental analysis
No fundamental analysis for Nuo Therapeutics Inc yet.
Nuo Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nuo Therapeutics Inc
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physician…
Full company profileNuo Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nuo Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.20M | 721K | 1.37M | 146K | 4.90K | 0.00 | 112K | 609K | 1.37M | 3.31M | 6.14M |
| Gross Profit | 592K | -370K | 1.21M | 31.6K | -12.7K | 0.00 | 93.0K | 482K | 1.06M | 2.22M | 4.04M |
| Operating Income | -7.80M | -6.23M | -1.50M | -969K | -378K | -90.7K | -3.32M | -3.17M | -2.46M | -2.52M | -1.23M |
| EBITDA | - | -13.9M | -1.40M | -973K | -42.5K | - | -3.10M | -3.06M | -2.36M | -2.36M | -1.05M |
| Net Income | 22.5M | -15.0M | -1.54M | -1.19M | -90.9K | -90.7K | -3.17M | -3.17M | -2.32M | -2.51M | -1.79M |
| EPS | - | -0.66 | -0.06 | -0.05 | 0.00 | 0.00 | -0.08 | -0.07 | -0.05 | -0.05 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 14.1M | 1.42M | 975K | 157K | 153K | 150K | 3.05M | 1.88M | 1.19M | 1.85M | 2.63M |
| Total Liabilities | 1.57M | 941K | 1.06M | 667K | 669K | 672K | 856K | 839K | 676K | 2.80M | 4.16M |
| Shareholders' Equity | 12.5M | 483K | -82.0K | -509K | -516K | -523K | 2.19M | 1.04M | 514K | -957K | -1.54M |
| Cash & Short-term Investments | 2.62M | 694K | 637K | 157K | 152K | 148K | 2.05M | 929K | 284K | 549K | 449K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.9M | -4.90M | -874K | -922K | -53.8K | -120K | -3.71M | -3.17M | -2.23M | -865K | -2.04M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 60.0K | 60.0K | 60.0K | 60.0K | 7.24K | 155K | 275K | 508K |
| Free Cash Flow | - | -4.90M | -874K | -4.17K | -9.85K | -13.0K | -3.77M | -3.18M | -2.39M | -1.14M | -2.55M |
| Ratios | |||||||||||
| ROE | 180.0% | -3,102.0% | - | - | - | - | -144.7% | -305.2% | -452.3% | - | - |
| ROA | 159.9% | -1,051.8% | -158.1% | -759.8% | -59.4% | -60.5% | -104.1% | -168.9% | -195.4% | -136.1% | -68.2% |
| Net Profit Margin | 1,019.6% | -2,077.4% | -112.5% | -817.4% | -1,854.5% | - | -2,825.6% | -521.2% | -170.2% | -75.8% | -29.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nuo Therapeutics Inc dividends
Nuo Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Nuo Therapeutics Inc
- Insiders 57.89%
- Institutions 0.01%
- Public & others 42.10%
- Shares outstanding 48.4M
- Free float 20.3M
Nuo Therapeutics Inc company profile
- Company name
- Nuo Therapeutics Inc
- Ticker
- AURX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 8285 El Rio, Houston, TX, United States, 77054
- Phone
- 346 396 4770
- Website
- nuot.com
About Nuo Therapeutics Inc
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Nuo Therapeutics Inc management
2- Mr. David E. Jorden CPACEO, CFO, Secretary & Executive Director · born 1962
- Dr. Peter Anton Clausen Ph.D.COO & Chief Scientific Officer · born 1966